Cargando…

Prevalence and risk of residual viremia after ART in low- and middle-income countries: A cross-sectional study

In order to design effective strategies to eradicate the HIV, an understanding of persistent viral reservoirs is needed. Many studies have demonstrated HIV residual viremia prevalence in high income countries, data from low- and middle-income countries (LMIC) are limited. We assessed the prevalence,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gatechompol, Sivaporn, Zheng, Lu, Bao, Yajing, Avihingsanon, Anchalee, Kerr, Stephen J., Kumarasamy, Nagalingeswaran, Hakim, James G., Maldarelli, Frank, Gorelick, Robert J., Welker, Jorden L., Lifson, Jeffrey D., Hosseinipour, Mina C., Eron, Joseph J., Ruxrungtham, Kiat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415996/
https://www.ncbi.nlm.nih.gov/pubmed/34477118
http://dx.doi.org/10.1097/MD.0000000000026817
_version_ 1783748083166740480
author Gatechompol, Sivaporn
Zheng, Lu
Bao, Yajing
Avihingsanon, Anchalee
Kerr, Stephen J.
Kumarasamy, Nagalingeswaran
Hakim, James G.
Maldarelli, Frank
Gorelick, Robert J.
Welker, Jorden L.
Lifson, Jeffrey D.
Hosseinipour, Mina C.
Eron, Joseph J.
Ruxrungtham, Kiat
author_facet Gatechompol, Sivaporn
Zheng, Lu
Bao, Yajing
Avihingsanon, Anchalee
Kerr, Stephen J.
Kumarasamy, Nagalingeswaran
Hakim, James G.
Maldarelli, Frank
Gorelick, Robert J.
Welker, Jorden L.
Lifson, Jeffrey D.
Hosseinipour, Mina C.
Eron, Joseph J.
Ruxrungtham, Kiat
author_sort Gatechompol, Sivaporn
collection PubMed
description In order to design effective strategies to eradicate the HIV, an understanding of persistent viral reservoirs is needed. Many studies have demonstrated HIV residual viremia prevalence in high income countries, data from low- and middle-income countries (LMIC) are limited. We assessed the prevalence, and factors associated with residual viremia in people with HIV (PWH), who were virally-suppressed on antiretroviral therapy (ART) in LMIC. We also compared residual viremia prevalence between the LMIC and US. This is a cross-sectional, retrospective study that utilized stored specimen samples from the AIDS clinical trials group (ACTG) studies A5175 and A5208. The last available sample among participants with plasma HIV RNA < 400 copies/mL for ≥3 years were tested by the HIV molecular and monitoring core gag (HMMCgag) single copy assay (SCA). Residual viremia was defined as detectable if ≥1 copy/mL. Spearman's correlation and multivariable stepwise logistic regression were used to assess associations of various factors with SCA. A total of 320 participants, 246 (77%) from LMIC and 74 (23%) from US, were analyzed. Median (IQR) age was 33 (2840) years; baseline CD4 166 (88,230) cells/mm(3); HIV RNA 5.0 (4.5, 5.3) log10 copies/mL; duration of viral suppression 3.4 (3.1, 4.0) years and 48% were male. In 85 participants with information available, 53% were subtype C, 42% subtype B and 5% other subtypes. Overall prevalence of residual viremia was 57% [95% CI, 52–63] with 51% [40–63] in US and 59% [53–65] in LMIC. Among participants with detectable SCA, the median (IQR) HIV RNA was 3.8 (2.2, 8.1) copies/mL. The multivariable model conducted in LMIC participants showed that higher baseline HIV RNA was associated with detectable residual RNA (OR 2.9, 95% CI 1.8, 4.6 for every log10 increase, P < .001). After including both US and LMIC in the final model, baseline HIV RNA remained significant. No difference in SCA detestability was found between US and LMIC sites (OR 1.1 [0.6, 2.0], P = .72) after adjusting for baseline RNA and parent study. The prevalence of residual viremia between both groups were not different and more than half of the participants had detectable viremia. Higher baseline HIV RNA was independently associated with residual viremia.
format Online
Article
Text
id pubmed-8415996
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-84159962021-09-07 Prevalence and risk of residual viremia after ART in low- and middle-income countries: A cross-sectional study Gatechompol, Sivaporn Zheng, Lu Bao, Yajing Avihingsanon, Anchalee Kerr, Stephen J. Kumarasamy, Nagalingeswaran Hakim, James G. Maldarelli, Frank Gorelick, Robert J. Welker, Jorden L. Lifson, Jeffrey D. Hosseinipour, Mina C. Eron, Joseph J. Ruxrungtham, Kiat Medicine (Baltimore) 4850 In order to design effective strategies to eradicate the HIV, an understanding of persistent viral reservoirs is needed. Many studies have demonstrated HIV residual viremia prevalence in high income countries, data from low- and middle-income countries (LMIC) are limited. We assessed the prevalence, and factors associated with residual viremia in people with HIV (PWH), who were virally-suppressed on antiretroviral therapy (ART) in LMIC. We also compared residual viremia prevalence between the LMIC and US. This is a cross-sectional, retrospective study that utilized stored specimen samples from the AIDS clinical trials group (ACTG) studies A5175 and A5208. The last available sample among participants with plasma HIV RNA < 400 copies/mL for ≥3 years were tested by the HIV molecular and monitoring core gag (HMMCgag) single copy assay (SCA). Residual viremia was defined as detectable if ≥1 copy/mL. Spearman's correlation and multivariable stepwise logistic regression were used to assess associations of various factors with SCA. A total of 320 participants, 246 (77%) from LMIC and 74 (23%) from US, were analyzed. Median (IQR) age was 33 (2840) years; baseline CD4 166 (88,230) cells/mm(3); HIV RNA 5.0 (4.5, 5.3) log10 copies/mL; duration of viral suppression 3.4 (3.1, 4.0) years and 48% were male. In 85 participants with information available, 53% were subtype C, 42% subtype B and 5% other subtypes. Overall prevalence of residual viremia was 57% [95% CI, 52–63] with 51% [40–63] in US and 59% [53–65] in LMIC. Among participants with detectable SCA, the median (IQR) HIV RNA was 3.8 (2.2, 8.1) copies/mL. The multivariable model conducted in LMIC participants showed that higher baseline HIV RNA was associated with detectable residual RNA (OR 2.9, 95% CI 1.8, 4.6 for every log10 increase, P < .001). After including both US and LMIC in the final model, baseline HIV RNA remained significant. No difference in SCA detestability was found between US and LMIC sites (OR 1.1 [0.6, 2.0], P = .72) after adjusting for baseline RNA and parent study. The prevalence of residual viremia between both groups were not different and more than half of the participants had detectable viremia. Higher baseline HIV RNA was independently associated with residual viremia. Lippincott Williams & Wilkins 2021-09-03 /pmc/articles/PMC8415996/ /pubmed/34477118 http://dx.doi.org/10.1097/MD.0000000000026817 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle 4850
Gatechompol, Sivaporn
Zheng, Lu
Bao, Yajing
Avihingsanon, Anchalee
Kerr, Stephen J.
Kumarasamy, Nagalingeswaran
Hakim, James G.
Maldarelli, Frank
Gorelick, Robert J.
Welker, Jorden L.
Lifson, Jeffrey D.
Hosseinipour, Mina C.
Eron, Joseph J.
Ruxrungtham, Kiat
Prevalence and risk of residual viremia after ART in low- and middle-income countries: A cross-sectional study
title Prevalence and risk of residual viremia after ART in low- and middle-income countries: A cross-sectional study
title_full Prevalence and risk of residual viremia after ART in low- and middle-income countries: A cross-sectional study
title_fullStr Prevalence and risk of residual viremia after ART in low- and middle-income countries: A cross-sectional study
title_full_unstemmed Prevalence and risk of residual viremia after ART in low- and middle-income countries: A cross-sectional study
title_short Prevalence and risk of residual viremia after ART in low- and middle-income countries: A cross-sectional study
title_sort prevalence and risk of residual viremia after art in low- and middle-income countries: a cross-sectional study
topic 4850
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415996/
https://www.ncbi.nlm.nih.gov/pubmed/34477118
http://dx.doi.org/10.1097/MD.0000000000026817
work_keys_str_mv AT gatechompolsivaporn prevalenceandriskofresidualviremiaafterartinlowandmiddleincomecountriesacrosssectionalstudy
AT zhenglu prevalenceandriskofresidualviremiaafterartinlowandmiddleincomecountriesacrosssectionalstudy
AT baoyajing prevalenceandriskofresidualviremiaafterartinlowandmiddleincomecountriesacrosssectionalstudy
AT avihingsanonanchalee prevalenceandriskofresidualviremiaafterartinlowandmiddleincomecountriesacrosssectionalstudy
AT kerrstephenj prevalenceandriskofresidualviremiaafterartinlowandmiddleincomecountriesacrosssectionalstudy
AT kumarasamynagalingeswaran prevalenceandriskofresidualviremiaafterartinlowandmiddleincomecountriesacrosssectionalstudy
AT hakimjamesg prevalenceandriskofresidualviremiaafterartinlowandmiddleincomecountriesacrosssectionalstudy
AT maldarellifrank prevalenceandriskofresidualviremiaafterartinlowandmiddleincomecountriesacrosssectionalstudy
AT gorelickrobertj prevalenceandriskofresidualviremiaafterartinlowandmiddleincomecountriesacrosssectionalstudy
AT welkerjordenl prevalenceandriskofresidualviremiaafterartinlowandmiddleincomecountriesacrosssectionalstudy
AT lifsonjeffreyd prevalenceandriskofresidualviremiaafterartinlowandmiddleincomecountriesacrosssectionalstudy
AT hosseinipourminac prevalenceandriskofresidualviremiaafterartinlowandmiddleincomecountriesacrosssectionalstudy
AT eronjosephj prevalenceandriskofresidualviremiaafterartinlowandmiddleincomecountriesacrosssectionalstudy
AT ruxrungthamkiat prevalenceandriskofresidualviremiaafterartinlowandmiddleincomecountriesacrosssectionalstudy